Cargando…
Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19
The prothrombotic and proinflammatory properties of lipoprotein(a) (Lp(a)) have been hypothesized to play a role in the pathogenesis of severe COVID-19; however, the prognostic impact of Lp(a) on the clinical course of COVID-19 remains controversial. This study aimed to investigate whether Lp(a) may...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218794/ https://www.ncbi.nlm.nih.gov/pubmed/37240653 http://dx.doi.org/10.3390/jcm12103543 |
_version_ | 1785048858385973248 |
---|---|
author | Bianconi, Vanessa Mannarino, Massimo R. Ramondino, Federica Fusaro, Jessica Giglioni, Francesco Braca, Marco Ricciutelli, Federica Lombardini, Rita Paltriccia, Rita Greco, Alessia Lega, Iliana C. Pirro, Matteo |
author_facet | Bianconi, Vanessa Mannarino, Massimo R. Ramondino, Federica Fusaro, Jessica Giglioni, Francesco Braca, Marco Ricciutelli, Federica Lombardini, Rita Paltriccia, Rita Greco, Alessia Lega, Iliana C. Pirro, Matteo |
author_sort | Bianconi, Vanessa |
collection | PubMed |
description | The prothrombotic and proinflammatory properties of lipoprotein(a) (Lp(a)) have been hypothesized to play a role in the pathogenesis of severe COVID-19; however, the prognostic impact of Lp(a) on the clinical course of COVID-19 remains controversial. This study aimed to investigate whether Lp(a) may be associated with biomarkers of thrombo-inflammation and the occurrence of thrombotic events or adverse clinical outcomes in patients hospitalized for COVID-19. We consecutively enrolled a cohort of patients hospitalized for COVID-19 and collected blood samples for Lp(a) assessment at hospital admission. A prothrombotic state was evaluated through D-dimer levels, whereas a proinflammatory state was evaluated through C-reactive protein (CRP), procalcitonin, and white blood cell (WBC) levels. Thrombotic events were marked by the diagnosis of deep or superficial vein thrombosis (DVT or SVT), pulmonary embolism (PE), stroke, transient ischemic attack (TIA), acute coronary syndrome (ACS), and critical limb ischemia (CLI). The composite clinical end point of intensive care unit (ICU) admission/in-hospital death was used to evaluate adverse clinical outcomes. Among 564 patients (290 (51%) men, mean age of 74 ± 17 years) the median Lp(a) value at hospital admission was 13 (10–27) mg/dL. During hospitalization, 64 (11%) patients were diagnosed with at least one thrombotic event and 83 (15%) patients met the composite clinical end point. Lp(a), as either a continuous or categorical variable, was not associated with D-dimer, CRP, procalcitonin, and WBC levels (p > 0.05 for all correlation analyses). In addition, Lp(a) was not associated with a risk of thrombotic events (p > 0.05 for multi-adjusted odds ratios) nor with a risk of adverse clinical outcomes (p > 0.05 for multi-adjusted hazard ratios). In conclusion, Lp(a) does not influence biomarkers of plasma thrombotic activity and systemic inflammation nor has any impact on thrombotic events and adverse clinical outcomes in patients hospitalized for COVID-19. |
format | Online Article Text |
id | pubmed-10218794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102187942023-05-27 Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19 Bianconi, Vanessa Mannarino, Massimo R. Ramondino, Federica Fusaro, Jessica Giglioni, Francesco Braca, Marco Ricciutelli, Federica Lombardini, Rita Paltriccia, Rita Greco, Alessia Lega, Iliana C. Pirro, Matteo J Clin Med Article The prothrombotic and proinflammatory properties of lipoprotein(a) (Lp(a)) have been hypothesized to play a role in the pathogenesis of severe COVID-19; however, the prognostic impact of Lp(a) on the clinical course of COVID-19 remains controversial. This study aimed to investigate whether Lp(a) may be associated with biomarkers of thrombo-inflammation and the occurrence of thrombotic events or adverse clinical outcomes in patients hospitalized for COVID-19. We consecutively enrolled a cohort of patients hospitalized for COVID-19 and collected blood samples for Lp(a) assessment at hospital admission. A prothrombotic state was evaluated through D-dimer levels, whereas a proinflammatory state was evaluated through C-reactive protein (CRP), procalcitonin, and white blood cell (WBC) levels. Thrombotic events were marked by the diagnosis of deep or superficial vein thrombosis (DVT or SVT), pulmonary embolism (PE), stroke, transient ischemic attack (TIA), acute coronary syndrome (ACS), and critical limb ischemia (CLI). The composite clinical end point of intensive care unit (ICU) admission/in-hospital death was used to evaluate adverse clinical outcomes. Among 564 patients (290 (51%) men, mean age of 74 ± 17 years) the median Lp(a) value at hospital admission was 13 (10–27) mg/dL. During hospitalization, 64 (11%) patients were diagnosed with at least one thrombotic event and 83 (15%) patients met the composite clinical end point. Lp(a), as either a continuous or categorical variable, was not associated with D-dimer, CRP, procalcitonin, and WBC levels (p > 0.05 for all correlation analyses). In addition, Lp(a) was not associated with a risk of thrombotic events (p > 0.05 for multi-adjusted odds ratios) nor with a risk of adverse clinical outcomes (p > 0.05 for multi-adjusted hazard ratios). In conclusion, Lp(a) does not influence biomarkers of plasma thrombotic activity and systemic inflammation nor has any impact on thrombotic events and adverse clinical outcomes in patients hospitalized for COVID-19. MDPI 2023-05-18 /pmc/articles/PMC10218794/ /pubmed/37240653 http://dx.doi.org/10.3390/jcm12103543 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bianconi, Vanessa Mannarino, Massimo R. Ramondino, Federica Fusaro, Jessica Giglioni, Francesco Braca, Marco Ricciutelli, Federica Lombardini, Rita Paltriccia, Rita Greco, Alessia Lega, Iliana C. Pirro, Matteo Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19 |
title | Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19 |
title_full | Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19 |
title_fullStr | Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19 |
title_full_unstemmed | Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19 |
title_short | Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19 |
title_sort | lipoprotein(a) does not predict thrombotic events and in-hospital outcomes in patients with covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218794/ https://www.ncbi.nlm.nih.gov/pubmed/37240653 http://dx.doi.org/10.3390/jcm12103543 |
work_keys_str_mv | AT bianconivanessa lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT mannarinomassimor lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT ramondinofederica lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT fusarojessica lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT giglionifrancesco lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT bracamarco lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT ricciutellifederica lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT lombardinirita lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT paltricciarita lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT grecoalessia lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT legailianac lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 AT pirromatteo lipoproteinadoesnotpredictthromboticeventsandinhospitaloutcomesinpatientswithcovid19 |